Can-Fite BioPharma (CANF) AI Stock Analysis

• Market Cap: $15.60M
• Dividend Yield: N/A
• Average Volume (3M): 258.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.98
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 17,072,916
• 10 Day Avg. Volume: 432,468
• 30 Day Avg. Volume: 258,053
• PEG Ratio: 0.04
• Price to Book (P/B): 2.18
• Price to Sales (P/S): 17.54
• P/FCF Ratio: -1.55
• Enterprise Value/Market Cap: 0.36
• Enterprise Value/Revenue: 9.96
• Enterprise Value/Gross Profit: 9.96
• Enterprise Value/Ebitda: -0.63
• 1Y Price Target: $2.50
• Price Target Upside: 509.76% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $0.50 ▲(21.95% Upside)

The overall stock score for Can-Fite BioPharma is low due to significant financial challenges, bearish technical indicators, and lack of valuation data. The company's declining revenues, persistent losses, and reliance on external financing are major concerns. Technical analysis indicates bearish momentum, with the stock trading below key moving averages and in oversold conditions.

Can-Fite BioPharma Business Overview & Revenue Model

Company Description

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer, inflammatory diseases, and liver diseases. The company is headquartered in Israel and specializes in the discovery and development of proprietary small molecule drugs, with its core products including Namodenoson, a novel drug candidate for liver cancer and other indications, as well as additional pipeline candidates targeting various conditions. Can-Fite's therapeutic approach is based on its understanding of the role of the A3 adenosine receptor in disease processes, positioning it in the biotechnology sector with a focus on unmet medical needs.

How the Company Makes Money

Can-Fite BioPharma generates revenue primarily through a combination of clinical trial funding, strategic partnerships, and potential licensing agreements. The company secures funding for its research and development through grants, collaborations with research institutions, and strategic partnerships with larger pharmaceutical companies, which may include milestone payments and royalties on future sales if products are commercialized. Additionally, Can-Fite has the potential to earn revenue from licensing its drug candidates to partners who wish to develop or market these therapies in specific regions, providing a financial incentive to continue advancing its product pipeline.

Can-Fite BioPharma Financial Statement Overview

Summary

Can-Fite BioPharma is facing significant financial challenges, with declining revenues, persistent losses, and reliance on external financing. Despite low leverage, the decreasing equity and continuous negative cash flow highlight potential sustainability risks.

Income Statement

Can-Fite BioPharma's income statement reveals significant challenges, with consistent negative EBIT and net income over the years, indicating ongoing operational inefficiencies. The company has experienced declining revenue, with a revenue decrease of approximately 9.3% from 2023 to 2024. Margins are negative, with a net profit margin of -1169% in 2024, highlighting profitability issues. Despite these challenges, the gross profit margin remains positive due to relatively low cost of goods sold.

Balance Sheet

The balance sheet shows a mixed picture. Can-Fite BioPharma maintains a low level of debt, with a debt-to-equity ratio of 0.019 in 2024, suggesting limited leverage risk. However, the stockholder's equity has been decreasing, indicating potential erosion in financial stability. The equity ratio stands at 59.6%, reflecting a moderate reliance on equity to finance assets. The decreasing equity may pose future risks if the trend continues.

Cash Flow

Cash flow analysis indicates consistent negative free cash flow, which is a concern for sustainability. However, the free cash flow has improved by 9.5% from 2023 to 2024. The operating cash flow to net income ratio is negative, indicating that operations are not generating sufficient cash to cover net losses. The company has relied on financing activities to sustain operations, as seen with substantial financing cash flow in recent years.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	560.00K	674.00K	743.00K	810.00K	853.00K	763.00K
Gross Profit	560.00K	674.00K	743.00K	810.00K	853.00K	763.00K
EBITDA	-8.90M	-8.12M	-8.18M	-10.08M	-12.83M	-14.13M
Net Income	-8.80M	-7.88M	-7.63M	-10.17M	-12.60M	-14.44M
Balance Sheet
Total Assets	7.72M	9.12M	9.99M	9.28M	20.25M	9.52M
Cash, Cash Equivalents and Short-Term Investments	6.46M	7.89M	8.92M	7.98M	19.14M	8.34M
Total Debt	90.00K	104.00K	40.00K	62.00K	124.00K	67.00K
Total Liabilities	3.54M	3.68M	3.75M	4.81M	5.87M	3.45M
Stockholders Equity	4.18M	5.44M	6.24M	4.47M	14.38M	6.07M
Cash Flow
Free Cash Flow	-8.36M	-7.64M	-8.44M	-10.81M	-9.87M	-12.09M
Operating Cash Flow	-8.35M	-7.64M	-8.44M	-10.80M	-9.86M	-12.06M
Investing Cash Flow	-2.00K	1.50M	498.00K	9.50M	-14.51M	-26.00K
Financing Cash Flow	10.08M	6.71M	9.14M	0.00	20.46M	17.68M

Can-Fite BioPharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CANF, the sentiment is Negative. The current price of 0.41 is below the 20-day moving average (MA) of 0.47, below the 50-day MA of 0.56, and below the 200-day MA of 1.04, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 25.14 is Positive, neither overbought nor oversold. The STOCH value of 12.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CANF.

Can-Fite BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHGE	44 Neutral	$10.70M	-0.40	-99.35%	―	―	80.30%
BCDA	43 Neutral	$14.01M	-0.61	―	―	-100.00%	60.53%
CANF	38 Underperform	$15.60M	―	―	―	―	―
PCSA	29 Underperform	$17.42M	-0.15	-270.74%	―	―	72.88%

Can-Fite BioPharma Corporate Events

Can-Fite BioPharma Announces Special Shareholder Meeting for Capital Restructuring

On October 3, 2025, Can-Fite BioPharma Ltd. announced it will hold a Special General Meeting of Shareholders on November 3, 2025, at its offices in Ramat Gan, Israel. The meeting will address two key proposals: increasing the company’s authorized share capital by 22 billion shares and approving a reverse stock split at a ratio of 1:3000. These actions are intended to enhance the company’s capital structure and potentially improve its market position. Shareholders and American Depositary Shareholders are invited to vote on these proposals, which are recommended by the company’s Board of Directors.

Can-Fite BioPharma Announces Breakthrough in Liver Disease Treatment with Namodenoson

On September 15, 2025, Can-Fite BioPharma announced a significant clinical finding in its compassionate use program for decompensated liver cirrhosis. A patient treated with Namodenoson showed a complete resolution of esophageal varices, a severe complication of advanced liver disease. This outcome, confirmed by endoscopic evaluation, suggests a potential disease-modifying effect of Namodenoson. The drug is currently in Phase III trials for hepatocellular carcinoma and has shown promise in treating other conditions, highlighting its therapeutic potential in a market with limited treatment options.

Can-Fite BioPharma Reports Mid-2025 Financial Results and Drug Development Updates

On August 28, 2025, Can-Fite BioPharma Ltd. announced its financial results for the first half of 2025 and provided updates on its drug development programs. The company released unaudited interim condensed consolidated financial statements as of June 30, 2025. These announcements are significant as they provide insights into the company’s financial health and progress in drug development, potentially impacting its market positioning and stakeholder interests.